

Evaluation of 3D-human skin equivalents for assessment of human dermal absorption of some brominated flame retardants

Abdallah, Mohamed; Pawar, Gopal; Harrad, Stuart

DOI:

[10.1016/j.envint.2015.07.015](https://doi.org/10.1016/j.envint.2015.07.015)

License:

Creative Commons: Attribution-NonCommercial-NoDerivs (CC BY-NC-ND)

Document Version

Peer reviewed version

Citation for published version (Harvard):

Abdallah, M, Pawar, G & Harrad, S 2015, 'Evaluation of 3D-human skin equivalents for assessment of human dermal absorption of some brominated flame retardants', *Environment International*, vol. 84, pp. 64-70.
<https://doi.org/10.1016/j.envint.2015.07.015>

[Link to publication on Research at Birmingham portal](#)

Publisher Rights Statement:

After an embargo period this document is subject to the terms of a Creative Commons Attribution Non-Commercial No Derivatives license

Checked October 2015

General rights

Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

- Users may freely distribute the URL that is used to identify this publication.
- Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
- User may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (?)
- Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

Take down policy

While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to the work immediately and investigate.

1 **EVALUATION OF 3D-HUMAN SKIN EQUIVALENTS FOR ASSESSMENT OF**
2 **HUMAN DERMAL ABSORPTION OF SOME BROMINATED FLAME**
3 **RETARDANTS**

4 Mohamed Abou-Elwafa Abdallah^{1,2*}, Gopal Pawar¹ and Stuart Harrad¹

5
6 ¹Division of Environmental Health and Risk Management,

7 College of Life and Environmental Sciences,

8 University of Birmingham,

9 Birmingham, B15 2TT,

10 United Kingdom.

11
12 ²Department of Analytical Chemistry

13 Faculty of Pharmacy, Assiut University

14 71526 Assiut,

15 Egypt

16
17 * Corresponding author

18 Email mae_abdallah@yahoo.co.uk

19 Tel. +44121 414 7297

20 Fax. +44121 414 3078

21
22
23
24

25 **Abstract**

26 Ethical and technical difficulties inherent to studies in human tissues are impeding
27 assessment of the dermal bioavailability of brominated flame retardants (BFRs). This is
28 further complicated by increasing restrictions on the use of animals in toxicity testing, and the
29 uncertainties associated with extrapolating data from animal studies to humans due to inter-
30 species variations. To overcome these difficulties, we evaluate 3D-human skin equivalents
31 (3D-HSE) as a novel *in vitro* alternative to human and animal testing for assessment of
32 dermal absorption of BFRs. The percutaneous penetration of hexabromocyclododecanes
33 (HBCD) and tetrabromobisphenol-A (TBBP-A) through two commercially available 3D-HSE
34 models was studied and compared to data obtained for human *ex vivo* skin according to a
35 standard protocol. No statistically significant differences were observed between the results
36 obtained using 3D-HSE and human *ex vivo* skin at two exposure levels. The absorbed dose
37 was low (less than 7%) and was significantly correlated with log K_{ow} of the tested BFR.
38 Permeability coefficient values showed increasing dermal resistance to the penetration of γ -
39 HBCD > β -HBCD > α -HBCD > TBBPA. The estimated long lag times (> 30 minutes)
40 suggests that frequent hand washing may reduce human exposure to HBCDs and TBBPA via
41 dermal contact.

42

43 Keywords: Dermal absorption, Human skin equivalents, Human *ex vivo* skin, HBCDs,
44 TBBPA, EPISKIN.

45

46

47 **Introduction**

48 Brominated flame retardants (BFRs) are a diverse group of chemicals widely used to prevent
49 or reduce the flammability and combustibility of polymers and textiles. Among the major
50 members of this group are Tetrabromobisphenol A (TBBP-A) and hexabromocyclododecane
51 (HBCD) with estimated global production volumes of 170,000 and 16,700 tons, respectively
52 (BSEF 2014). Since HBCD and ~20% of the produced TBBP-A are blended physically
53 within, rather than bound chemically to polymeric materials; they migrate from products,
54 following which their persistence and bioaccumulative character leads to contamination of
55 the environment including humans (Harrad, et al. 2010). This is of concern owing to their
56 potential toxicological risks including: endocrine disruption, neurodevelopmental and
57 behavioral disorders, hepatotoxicity and possibly cancer (Darnerud 2008; Wikoff and
58 Birnbaum 2011). Such evidence has contributed to several regulations (e.g. REACH) under
59 different jurisdictions to control the production and use of these hazardous chemicals.
60 Recently, HBCD was listed under Annex A of the Stockholm Convention on Persistent
61 Organic Pollutants (POPs) (UNEP 2014).

62 Substantial data exist on concentrations of different FRs in various environmental and human
63 matrices (Covaci, et al. 2009; Law, et al. 2014; van der Veen and de Boer 2012). Current
64 understanding is that non-occupational human exposure to BFRs occurs mainly via a
65 combination of diet, ingestion of indoor dust, dermal contact with dust/consumer products,
66 and inhalation of indoor air (Abdallah, et al. 2008a; Frederiksen, et al. 2009; Watkins, et al.
67 2011). The exact contribution of these pathways varies substantially between chemicals,
68 between individuals according to lifestyle, and is further complicated by international
69 variations in FR use (Abdallah and Harrad 2009; Abdallah, et al. 2008a; Abdallah, et al.
70 2008b).

71 Currently, very little is known about dermal uptake as a route of human exposure to BFRs in

72 indoor dust or flame-retarded products. Watkins et al. reported a significant positive
73 correlation between PBDE levels on hand wipes (presumably resulting from hand contact
74 with contaminated dust or flame-retarded products) and PBDE levels in blood serum from
75 American adults. While concentrations of PBDEs in indoor dust were strongly correlated
76 with those in hand wipes, correlation could not be established directly between PBDE
77 concentrations in indoor dust and their levels in serum (Watkins, et al. 2011). This opens up
78 the possibility that FRs in dust may also be an indicator of another exposure pathway, such as
79 direct dermal uptake of FRs present in treated goods (e.g. games consoles, remote controls,
80 and fabrics). However, the absence of experimental data on human dermal absorption of
81 various BFRs was recently highlighted as a major research gap hampering their accurate
82 exposure assessment. Efforts to fill this gap are currently impeded by several difficulties
83 including: ethical and technical issues inherent to studies involving human tissues, increasing
84 restrictions on the use of laboratory animals in toxicological studies and the substantial
85 uncertainties associated with extrapolating data from animal studies to humans due to inter-
86 species variation (e.g. skin barrier function, hair follicles, intercellular subcutaneous lipids
87 ...etc) (Abdallah, et al. 2015a).

88 To overcome these difficulties, this study will evaluate the application of *in vitro* 3D-human
89 skin equivalents (3D-HSE) as an alternative method to animal and human testing for
90 assessment of dermal uptake of HBCDs and TBBPA. 3D-HSE are commercially available,
91 fully differentiated, multi-layered dermal tissues that closely mimic the original human skin
92 histologically and physiologically (Schaefer-Korting, et al. 2008a). 3D-HSE consist mainly
93 of primary human cells (e.g. keratinocytes and fibroblasts) obtained from healthy consenting
94 donors, which are then cultured at the air-liquid interphase on a specially designed inert
95 support that allows cell growth in a nutrient culture medium (Figure SI-1). While cells grown
96 in 2D monolayers (e.g. Caco-2 cell models) cannot capture the relevant complexity of the *in*

97 *in vivo* microenvironment as they lack a myriad of important signals, key regulators, and tissue
98 phenotypes; cells growing in 3D tissue cultures have different cell surface receptor
99 expression, proliferative capacity, extracellular matrix synthesis, cell density, and metabolic
100 functions that resemble closely the original human tissue (Brohem, et al. 2011).
101 Consequently, validated protocols using 3D-HSE models have been approved by the OECD
102 (Organisation for Economic Co-operation and Development) and ECVAM (European Centre
103 for Validation of Alternative Methods) for testing skin irritation, phototoxicity and corrosion
104 by xenobiotic chemicals (Ackermann, et al. 2010; Buist, et al. 2010).

105 While 3D-HSE have been successfully applied within the cosmetics and pharmaceutical
106 sectors to study dermal uptake of various drugs (Ackermann, et al. 2010; Schaefer-Korting, et
107 al. 2008a), this study of dermal uptake of BFRs, is the first application of 3D-HSE to better
108 understanding of human dermal uptake of environmental contaminants. Our overall objective
109 was to demonstrate the substantial potential of these models to transform how human dermal
110 exposure to such contaminants is assessed. Nested within this, our specific aims were to: (a)
111 develop and apply a standard protocol for assessment of percutaneous penetration of HBCDs
112 and TBBPA using 2 commercially available 3D-HSE models (EPISKIN™ and EpiDerm™)
113 according to the OECD guidelines; (b) compare the results of 3D-HSE models to those
114 obtained from *in vitro* excised human skin (*ex vivo* skin); and (c) provide the first insights
115 into the dermal bioavailability of our target BFRs in humans.

116

117 **Materials and Methods**

118 Experiments were performed along the principles of good laboratory practice and in
119 compliance with the OECD guidelines for *in vitro* dermal absorption testing (OECD 2004).
120 The handling instructions and performance characteristics of the tested 3D-HSE models were
121 also taken into consideration. The study protocol received the required ethical approval (#

122 *ERN_12-1502*) from the University of Birmingham's Medical, Engineering and Mathematics
123 Ethical Review Committee.

124

125 *Test matrices.*

126 The EpiDerm™ *EPI-212-X* human skin equivalent kit was purchased from MatTek
127 Corporation (Ashland, MA). The *EPI-212-X* tissue constructs are 0.64 cm² human skin
128 equivalents resembling the normal human epidermis histologically and physiologically
129 (www.mattek.com). The kit includes maintenance medium (MM) - which is a proprietary
130 DMEM (Dulbecco's Modified Eagle's Medium)-based medium - that allows acceptable
131 differentiated morphology of the tissue for ~ 5 days upon receipt by end users.

132 The EPISKIN™ RHE/L/13 human skin equivalent kit was purchased from SkinEthic
133 Laboratories (Lyon, France). The RHE/L/13 tissue constructs are 1.07 cm² supplied with
134 enough MM to allow acceptable tissue differentiation (www.episkin.com). Upon receipt, the
135 EPISKIN™ and EpiDerm™ tissues were equilibrated overnight with their MM at 5% CO₂
136 and 37 °C before use in the permeation experiments.

137 Fresh excised human upper breast skin was obtained via Caltag Medsystems Ltd.
138 (Buckingham, UK) from 3 consented female adults (aged 36, 33 and 37 years) following
139 plastic surgery. Selection criteria included: Caucasian, no stretchmarks, no scars and no hair.
140 Full thickness skin without adipose tissue and an overall thickness of 550 ± 80 µm was used.
141 Upon receipt, the *ex vivo* skin samples were equilibrated for 1 hour with 3 mL of DMEM-
142 based (Sigma-Aldrich, UK) culture medium (Table SI-1) at 5% CO₂ and 37 °C before use in
143 permeation experiments.

144

145 *Dosing Solutions*

146 According to the OECD guidelines (OECD 2004), two different concentration levels of (I) 5

147 ng/ μ L and (II) 10 ng/ μ L of each of α -HBCD, β -HBCD, γ -HBCD and TBBP-A (Wellington
148 Laboratories Inc., ON, Canada) were prepared in acetone. Based on the exposed surface area,
149 a net dose of 500 ng/cm² (~7.8 μ M/cm²) and 1000 ng/cm² (~15.6 μ M/cm²) was applied to
150 each of the investigated skin tissues using an appropriate volume (100 μ L) of dosing
151 solutions I and II, respectively. The applied doses fall within the range of potential human
152 exposure to the studied BFRs via contact with indoor dust (Abdallah, et al. 2008a). Moreover,
153 they allow for measurement of expected low percentages (up to 0.01%) of the applied dose in
154 various compartments of the exposure model.

155 To study the possible effect of the dosing vehicle on the percutaneous penetration of the
156 tested chemicals, target BFRs were dissolved in 3 different dosing vehicles of: (A) acetone,
157 (B) 30% acetone in water, and (C) 20% Tween 80 (Sigma-Aldrich, UK) in water at a
158 concentration of 5 ng/ μ L. Preparation of the higher dosing level (i.e. 10 ng/ μ L) was not
159 possible due to limited solubility of target BFRs in vehicles (B) and (C).

160

161 *Permeation assay protocol*

162 The permeation experiments were performed using the static set-up approach (Figure 1). Skin
163 tissues were mounted in standard Franz-type permeation devices with *stratum corneum*
164 facing up. Based on the recommendation of the 3D-HSE providers, the EpiDerm™ tissues
165 were mounted in specifically designed MatTek™ permeation devices (MatTek Corporation,
166 Ashland, MA), the EPISKIN™ tissues were mounted in special inserts constructed for this
167 model (SkinEthic Laboratories, Lyon, France), while excised human skin tissues were
168 mounted in standard glass Franz cells.

169 All experiments were performed in triplicate. Following 30 minutes equilibration, the tested
170 chemicals were applied onto the skin surface in the donor compartment. A DMEM-based
171 culture medium (Table SI-1) was used as receptor fluid, maintained at 32 \pm 1 $^{\circ}$ C and

172 magnetically stirred. To comply with the OECD guidelines, 5% bovine serum albumin (BSA)
173 was added to the receptor fluid (Table SI-1) to enhance the solubility of target analytes, while
174 the levels of test compounds in the donor solutions were chosen to ensure that the
175 concentrations in the receptor fluid during the experiment did not exceed 10% of the
176 saturation solubility.

177 At fixed time points (0.25, 0.5, 0.75, 1, 2, 4, 6, 10, 12, 18, 20 and 24 h), aliquots of the
178 receptor fluid (2 mL) were collected from the receptor compartment and immediately
179 replaced with fresh fluid. After 24 hours, the entire receptor fluid was collected and the skin
180 surface washed thoroughly with cotton buds impregnated in (1:1) hexane:ethyl acetate (5
181 times). The tissues were removed from the permeation devices and both the donor and
182 receptor compartments were washed separately (5 x 2 mL) with (1:1) hexane:ethyl acetate.
183 All samples were stored at -20 °C until chemical analysis.

184

185 *Sample extraction and chemical analysis*

186 Each permeation assay generated five different types of samples comprising: receptor fluid at
187 various time points, skin tissue, cotton buds (used to thoroughly wipe the skin surface), donor
188 and receptor compartment washes.

189 The receptor fluid, skin tissue and cotton bud samples were extracted according to a
190 previously reported QuEChERS-based method (Abdallah, et al. 2015b) (more details in the
191 supplementary data section).

192 The donor and receptor compartment washes were spiked with 30 ng of the ¹³C-labeled
193 internal standard mixture prior to direct evaporation under a gentle stream of N₂. Target
194 analytes were reconstituted in 100 µL of methanol containing 100 pg/µL d₁₈- α-HBCD used
195 as recovery determination (syringe) standard for QA/QC purposes.

196 Instrumental analysis was carried out using an LC-MS/MS system composed of a dual pump

197 Shimadzu LC-20AB Prominence liquid chromatograph equipped with SIL-20A autosampler,
198 a DGU-20A3 vacuum degasser coupled to a Sciex API 2000 triple quadrupole mass
199 spectrometer. Details of the multi-residue analytical methodology used for separation and
200 quantification of the studied BFRs can be found elsewhere (Abdallah and Harrad 2011), with
201 a brief description provided as supplementary data.

202

203 *Data analysis and statistical methods*

204 A quantitative description of test compound permeation through the skin barrier is obtained
205 from Fick's first law of diffusion as follows (Niedorf, et al. 2008):

$$J_{ss} = \frac{\Delta m}{\Delta t \cdot A} = \frac{D \cdot K \cdot \Delta C}{\Delta x} \quad (1)$$

206 Where J_{ss} = steady-state flux [$\text{ng}/\text{cm}^2 \cdot \text{h}$]; Δm = permeated mass [ng]; Δt = time interval [h]; D
207 = diffusion coefficient [cm^2/h]; K = partition coefficient; A = area [cm^2]; Δc = concentration
208 difference [ng/cm^3]; Δx : thickness of membrane [cm].

209 When using infinite-dose configurations, i.e. in which the donor concentration far exceeds the
210 concentration in the receptor compartment ($C_D \gg C_A$), ΔC can be replaced by the known
211 donor concentration, C_D , and the permeated mass per time assumed constant. Therefore, the
212 apparent permeation coefficient (P_{app}), which represents an independent measure of the
213 membrane resistance against permeation of the examined substance, can be calculated as:

$$P_{app} = \frac{J_{ss}}{C_D} \quad (2)$$

214 For each permeation experiment, cumulative amounts of the permeated compounds in the
215 receptor fluid per unit area (ng/cm^2) were plotted versus time (hours). Steady state conditions
216 were indicated by a linear regression line ($R^2 \geq 0.9$), the slope of which represents the flux
217 (J_{ss}). Determination of the start and upper boundary of the linear range (i.e. steady state
218 conditions) was achieved according to the method described by Niedorf et al. (Niedorf, et al.

219 2008) (a summary flow chart is provided in figure SI-2).
220 Results are presented as the arithmetic mean of 3 replicates \pm standard deviation (SD).
221 Statistical analysis was performed using SPSS 13.0 software package. Differences in skin
222 permeation were evaluated by the paired student t-test between 2 datasets. A Games-Howell
223 test was used for analysis of variance (ANOVA) among several datasets with equal variances
224 not assumed; $p < 0.05$ was regarded to indicate a statistically significant difference.

225

226 *QA/QC*

227 Several stages of QA/QC measurements were performed to check the performance of
228 permeation assay protocol. A “field” blank, comprising a skin tissue exposed to solvents only
229 and treated as a sample, was performed with each sample batch (n= 9). None of the studied
230 compounds were above the limit of detection (LOD) in the field blank samples. Good
231 recoveries of the ^{13}C -labeled internal standards ($> 80\%$) were obtained indicating high
232 efficiency of the extraction method (Table SI-3).

233 Based on the guidelines of EPISKINTM and EpiDermTM models, the viability of the tissue was
234 tested by MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay using a
235 standard kit purchased from each provider. Acceptable MTT results (i.e. Formazan
236 concentration ≥ 1.5 mg/ml) were achieved following 24 hours of exposure. Both positive and
237 negative control experiments were carried out alongside each sample batch. Positive controls
238 involved the exposure of the test tissue to Triton-X-100 which showed $\sim 100\%$ permeation
239 (n=5; $97 \pm 4\%$), while negative controls showed 0% penetration of decabromodiphenyl
240 ethane after 24 hours exposure. The integrity of the skin membrane was tested using the
241 standard trans-epidermal electrical resistance (TEER) and methylene blue (BLUE) standard
242 methods (Guth, et al. 2015). One excised human skin patch failed the membrane integrity
243 test; hence its results were excluded from this study.

244

245 **Results and Discussion**

246 *Mass balance and absorbed fractions*

247 The efficiency of the experimental approach was investigated using a mass balance exercise.
248 Results revealed good overall recoveries (>85%) for the target compounds using different
249 permeation devices (Table 1). However, the use of specifically-designed permeation devices
250 for the EPISKIN™ and EpiDerm™ models minimized the formation of air bubbles
251 underneath the skin surface and reduced the handling-time and operator involvement during
252 sampling of the receptor fluid at different time points.

253 For simplicity, results of the permeation experiments were grouped under three major
254 compartments: The directly absorbed dose (cumulative concentration in the receptor fluid
255 over 24 h + receptor compartment rinse), the skin (concentration in the skin tissue after 24 h)
256 and the unabsorbed dose (concentration in the skin surface wipes after 24 h + donor
257 compartment rinse). Experimental results revealed higher permeation of all target compounds
258 in the following order: EpiDerm™ >EPISKIN™ > Human *ex vivo* skin at the two
259 concentration levels studied (Table 1 and Table SI-4). However, statistical analysis showed
260 no significant differences ($P > 0.05$) among the levels of target analytes in the 3 major
261 compartments of the examined tissues. Border line statistical significances ($P = 0.053$ and
262 0.056) were observed between the results of human *ex vivo* skin and those of EpiDerm™ for
263 β -HBCD and EPISKIN™ for TBBPA, respectively. The EpiDerm™ model displayed the
264 largest permeation difference from human *ex vivo* skin with ~25% increase in the permeated
265 dose of β -HBCD over 24 hours exposure.

266 Previous studies comparing percutaneous permeation of chemicals through different *in vitro*
267 models reported substantial inter-model differences. A 7-fold higher flux was observed for 11
268 pesticides across *in vitro* rat skin compared to human skin (van Ravenzwaay and Leibold

269 2004). For triclosan, a 3-fold higher dermal absorption in rat compared to human skin was
270 observed, while an 8-fold increase in the absorbed dose was reported for BDE-47 (Roper, et
271 al. 2006). Mouse skin showed higher permeability to several chemicals, *in vitro*, than either
272 rat, pig or human skin (Hughes, et al. 2001). A comparative study conducted in 2006
273 according to OECD guidelines reported less penetration of testosterone in pig and bovine
274 skin (0.07 and 0.13 % of applied dose) compared to human skin (0.32 %), while EPISKIN™
275 and EpiDerm™ models showed higher permeations (0.53 and 2.36, respectively) (Schafer-
276 Korting, et al. 2006). It is noteworthy that both 3D-HSE producers claim that their skin
277 models were further developed since 2006 to improve the barrier function. Hence the
278 EPISKIN™ and EpiDerm™ models used in this study are listed under the “enhanced barrier
279 function” category, which is different from those used in the 2006 study. Another well-
280 designed study reported higher diffusion of radiolabeled bisphenol A (BPA) through pig ear
281 skin (65%) compared to human skin (45%), although the difference was not statistically
282 significant at the 95% confidence level (Zalko, et al. 2011).

283 Investigation of the directly absorbed dose through the tested skin models showed a uniform
284 pattern of increasing permeation in the following order: TBBP-A > α -HBCD > β -HBCD > γ -
285 HBCD (Figure 2). This is generally in line with the physicochemical properties of the tested
286 compounds, where TBBP-A has a lower mass and higher water solubility than HBCDs
287 (Table SI-6). Furthermore, a statistically significant correlation ($P < 0.05$) was observed
288 between the 24 h cumulative absorbed dose and the log K_{OW} (Table SI-6) of the studied BFRs
289 in all the tested *in vitro* models. This highlights the influence of physicochemical properties
290 on the human dermal bioavailability of a chemical.

291

292 *Dermal flux (J_{ss}) and permeation coefficients (P_{app})*

293 A plot of the cumulative absorbed mass of each target compound (ng/cm^2) against time
294 (hours) was used to estimate the J_{ss} ($\text{ng}/\text{cm}^2 \cdot \text{h}$) for each target BFR and the P_{app} (cm/h) for the
295 examined skin models (Table 2). The steady state range of the curve was identified
296 according to the method reported by Niedorf et al. (Niedorf, et al. 2008), with a minimum of
297 5 data points in the linear range required to establish each curve (Figure SI-3, Table SI-5).
298 Following the application of a test compound to the skin, it needs to partition into and diffuse
299 through the skin before reaching the receptor fluid. This results in a lag-time, t_{lag} , with non-
300 detectable flux. The t_{lag} is represented by the time intercept (i.e. x-axis intercept) of the
301 regression line over the steady-state region of the permeation curve (Figure SI-3). Hence, t_{lag}
302 can be calculated from equation 3:

$$t_{lag} = \frac{b_0}{J_{ss}} \dots \dots \dots (3)$$

303 Where b_0 refers to the y-axis intercept of the linear regression line and J_{ss} is the slope.
304 Steady state flux (J_{ss}) provides quantitative description of a xenobiotic permeation through
305 the dermal barrier. This is expressed as the rate ($\text{ng}/\text{cm}^2 \cdot \text{h}$) by which the tested chemical
306 traverses the skin tissue to reach the receptor fluid (Niedorf, et al. 2008). With γ -HBCD
307 showing lowest percutaneous penetration and TBBPA the highest, J_{ss} of the studied BFRs
308 ranged from 0.8 - 1.5 $\text{ng}/\text{cm}^2 \cdot \text{h}$, 0.9 - 1.5 $\text{ng}/\text{cm}^2 \cdot \text{h}$ and 0.7 - 1.3 $\text{ng}/\text{cm}^2 \cdot \text{h}$ for the
309 EPISKINTM, EpiDermTM and human *ex vivo* skin, respectively (Table 2). Interestingly, α -
310 HBCD showed a consistently higher flux across skin than γ -HBCD at the studied doses
311 (Table 2). This indicates a higher dermal bioavailability of α -HBCD compared to the β - and
312 γ - isomers. In addition to slower biotransformation rates (Abdallah, et al. 2014) and higher
313 uptake from the gastrointestinal tract (Abdallah, et al. 2012), the greater dermal
314 bioavailability of α -HBCD is likely a contributory factor in the dramatic shift of the HBCD
315 isomeric profile from predominantly γ -HBCD in the commercial formulations and abiotic
316 samples to a predominance of α -HBCD in biota (Covaci, et al. 2006).

317 The estimated P_{app} values indicate more resistance of human *ex vivo* skin to the penetration of
318 target BFRs than the EPISKIN™ and EpiDerm™ models. However, this difference was not
319 statistically significant. In addition, both 3D-HSE models and human *ex vivo* skin displayed
320 increasing resistance to the penetration of BFRs in the same order of γ -HBCD > β -HBCD >
321 α -HBCD > TBBP-A.

322 The lipophilic nature, low polarity and low water solubility of the studied BFRs are
323 manifested by long lag times (> 30 minutes; Table 2), which suggests that frequent hand
324 washing may reduce human exposure to HBCDs and TBBPA via dermal contact. This is
325 generally in line with the results of Watkins et al. who found that adults washing their hands
326 fewer than four times/day had, on average, 3.3 times more pentaBDE in their handwipes
327 compared with those who washed their hands four or more times/day and concluded that
328 frequent hand washing may decrease exposure to PBDEs via dermal contact (Watkins, et al.
329 2011).

330

331 *Effect of dosing vehicle*

332 Several studies in the pharmaceutical and cosmetic sectors have highlighted the influence of
333 dosing vehicle on the percutaneous penetration of chemicals. However, these experiments
334 were exclusively based on aqueous solutions and topical emulsions (Schaefer-Korting, et al.
335 2008b). Very little is known about the quantitative effects of organic-based vehicles on the
336 dermal penetration of xenobiotics. In general, a vehicle may hydrate the stratum corneum
337 (SC), extract critical barrier components out of the skin, or damage the skin because it is a
338 strong acid or base. Removing SC lipids may increase percutaneous absorption of drugs.
339 Many organic solvents (e.g. chloroform and methanol) are employed to delipidize the skin,
340 which increases the permeability of hydrophilic - but not lipophilic – compounds (Chiang, et
341 al. 2012).

342 Since BFRs are highly lipophilic compounds with very low water solubility (Table SI-6), the
343 few studies on their dermal absorption used organic vehicles to dissolve the target analytes.
344 Hughes et al. used tetrahydrofuran (THF) as a vehicle for BDE-209 (Hughes, et al. 2001),
345 while Roper et al. used acetone for dissolving BDE-47 (Roper, et al. 2006). In the current
346 study, acetone was selected as the major dosing vehicle. This was based on its ability to
347 dissolve the test compounds at the desired levels and its minimal effect on skin barrier
348 functions. Abrams et al. studied the effect of various organic solvents on the trans-epidermal
349 water loss (TEWL) as an indicator of skin barrier. Both acetone and hexane showed no
350 significantly different effects than water, while a mixture of chloroform : methanol (2:1)
351 caused the greatest significant increase in TEWL (Abrams, et al. 1993).

352 To further investigate the potential effect of the dosing vehicle on percutaneous penetration
353 of BFRs, human *ex vivo* skin and the EPISKIN™ model were exposed to 500 ng/cm² of
354 target BFRs in each of : (A) acetone, (B) 30% acetone in water, and (C) 20% Tween 80 in
355 water for 24 h. Results revealed higher levels of target compounds were absorbed from
356 vehicle C, which was more evident for TBBP-A and α -HBCD compared to β - and γ -HBCDs
357 (Figures 3 and SI-4). This is in agreement with the reported enhancement of the dermal
358 absorption of testosterone in the presence of surfactants including miglyol and Tween 80
359 (Schaefer-Korting, et al. 2008b).

360 Although the differences in permeation of the studied BFRs from the tested vehicles lacked
361 statistical significance, the enhanced permeation of TBBP-A and α -HBCD (Figure 3) in the
362 presence of Tween 80 is potentially pertinent within the context of human exposure. This is
363 owing to the presence of natural surface active agents in human skin surface film
364 (sweat/sebum mixture) (Stefaniak, et al. 2010), which may influence the dermal absorption of
365 these BFRs. Therefore, detailed study of the effect of human skin surface film on the dermal
366 uptake of various BFRs appears warranted in the near future. In conclusion, the data

367 presented here demonstrate the validity of the 3D-HSE models for studying human dermal
368 uptake of BFRs and related environmental contaminants.

369

370 **Acknowledgement**

371 The research leading to these results has received funding from the European Union Seventh
372 Framework Programme FP7/2007-2013 under grant agreements 327232 (ADAPT project)
373 and 316665 (A-TEAM project). Further support was provided by Restek Corporation.

374

375 **Supplementary data**

376 Further details of the analytical methodology, quality assurance/quality control parameters
377 and distribution of target BFRs in different compartments of the *in vitro* diffusion system are
378 available as supplementary data.

379

380

381

382

383

384

385

386

387

388

389

390

391

392 **References**

- 393 Abdallah, M.A.-E.; Harrad, S. Personal exposure to HBCDs and its degradation products via
394 ingestion of indoor dust. *Environ Int.* 35:870-876; 2009
- 395 Abdallah, M.A.-E.; Harrad, S. Tetrabromobisphenol-A, hexabromocyclododecane and its
396 degradation products in UK human milk: Relationship to external exposure. *Environ Int.*
397 37:443-448; 2011
- 398 Abdallah, M.A.; Harrad, S.; Covaci, A. Hexabromocyclododecanes and tetrabromobisphenol-
399 A in indoor air and dust in Birmingham, U.K: implications for human exposure. *Environ*
400 *Sci Technol.* 42:6855-6861; 2008a
- 401 Abdallah, M.A.; Uchea, C.; Chipman, J.K.; Harrad, S. Enantioselective Biotransformation of
402 Hexabromocyclododecane by in Vitro Rat and Trout Hepatic Sub-Cellular Fractions.
403 *Environ Sci Technol.* 48:2732-2740; 2014
- 404 Abdallah, M.A.E.; Harrad, S.; Ibarra, C.; Diamond, M.; Melymuk, L.; Robson, M., et al.
405 Hexabromocyclododecanes in indoor dust from Canada, the United Kingdom, and-the
406 United States. *Environ Sci Technol.* 42:459-464; 2008b
- 407 Abdallah, M.A.E.; Pawar, G.; Harrad, S. Evaluation of in vitro vs. in vivo methods for
408 assessment of dermal absorption of organic flame retardants: A review. *Environ Int.*
409 74:13-22; 2015a
- 410 Abdallah, M.A.E.; Tilston, E.; Harrad, S.; Collins, C. In vitro assessment of the
411 bioaccessibility of brominated flame retardants in indoor dust using a colon extended
412 model of the human gastrointestinal tract. *J Environ Monitor.* 14:3276-3283; 2012
- 413 Abdallah, M.A.E.; Zhang, J.K.; Pawar, G.; Viant, M.R.; Chipman, J.K.; D'Silva, K., et al.
414 High-resolution mass spectrometry provides novel insights into products of human
415 metabolism of organophosphate and brominated flame retardants. *Anal Bioanal Chem.*
416 407:1871-1883; 2015b

417 Abrams, K.; Harvell, J.D.; Shriner, D.; Wertz, P.; Maibach, H.; Maibach, H.I., et al. Effect of
418 organic-solvents on in-vitro human skin water barrier function. *J Invest Dermatol.*
419 101:609-613; 1993

420 Ackermann, K.; Borgia, S.L.; Korting, H.C.; Mewes, K.R.; Schafer-Korting, M. The Phenion
421 full-thickness skin model for percutaneous absorption testing. *Skin Pharmacol Physiol.*
422 23:105-112; 2010

423 Brohem, C.A.; da Silva Cardeal, L.B.; Tiago, M.; Soengas, M.S.; de Moraes Barros, S.B.;
424 Maria-Engler, S.S. Artificial skin in perspective: concepts and applications. *Pigment Cell*
425 *& Melanoma Research.* 24:35-50; 2011

426 BSEF. Bromine Science and Environmental Forum. www.bsef.com; 2014

427 Buist, H.E.; van Burgsteden, J.A.; Freidig, A.P.; Maas, W.J.; van de Sandt, J.J. New in vitro
428 dermal absorption database and the prediction of dermal absorption under finite conditions
429 for risk assessment purposes. *Regul Toxicol Pharmacol.* 57:200-209; 2010

430 Chiang, A.; Tudela, E.; Maibach, H.I. Percutaneous absorption in diseased skin: an overview.
431 *J Appl Toxicol.* 32:537-563; 2012

432 Covaci, A.; Gerecke, A.C.; Law, R.J.; Voorspoels, S.; Kohler, M.; Heeb, N.V., et al.
433 Hexabromocyclododecanes (HBCDs) in the environment and humans: a review. *Environ*
434 *Sci Technol.* 40:3679-3688; 2006

435 Covaci, A.; Voorspoels, S.; Abdallah, M.A.; Geens, T.; Harrad, S.; Law, R.J. Analytical and
436 environmental aspects of the flame retardant tetrabromobisphenol-A and its derivatives. *J*
437 *Chromatogr A.* 1216:346-363; 2009

438 Darnerud, P.O. Brominated flame retardants as possible endocrine disrupters. *Int J Androl.*
439 31:152-160; 2008

440 Frederiksen, M.; Vorkamp, K.; Thomsen, M.; Knudsen, L.E. Human internal and external
441 exposure to PBDEs--a review of levels and sources. *Int J Hyg Environ Health*. 212:109-
442 134; 2009

443 Guth, K.; Schaefer-Korting, M.; Fabian, E.; Landsiedel, R.; van Ravenzwaay, B. Suitability
444 of skin integrity tests for dermal absorption studies in vitro. *Toxicol in Vitro*. 29:113-123;
445 2015

446 Harrad, S.; de Wit, C.A.; Abdallah, M.A.; Bergh, C.; Bjorklund, J.A.; Covaci, A., et al.
447 Indoor Contamination with Hexabromocyclododecanes, Polybrominated Diphenyl Ethers,
448 and Perfluoroalkyl Compounds: An Important Exposure Pathway for People? *Environ Sci*
449 *Technol*. 44:3221-3231; 2010

450 Hughes, M.F.; Edwards, B.C.; Mitchell, C.T.; Bhooshan, B. In vitro dermal absorption of
451 flame retardant chemicals. *Food Chem Toxicol*. 39:1263-1270; 2001

452 Law, R.J.; Covaci, A.; Harrad, S.; Herzke, D.; Abdallah, M.A.E.; Fernie, K., et al. Levels and
453 trends of PBDEs and HBCDs in the global environment: Status at the end of 2012.
454 *Environ Int*. 65:147-158; 2014

455 Niedorf, F.; Schmidt, E.; Kietzmann, M. The automated, accurate and reproducible
456 determination of steady-state permeation parameters from percutaneous permeation data.
457 *Alternatives to laboratory animals : ATLA*. 36:201-213; 2008

458 OECD. Guideline for the testing of chemicals. Skin absorption: in vitro method. Organisation
459 for Economic Cooperation and Development TG 428; 2004

460 Roper, C.S.; Simpson, A.G.; Madden, S.; Serex, T.L.; Biesemeier, J.A. Absorption of C-14 -
461 tetrabromodiphenyl ether (TeBDE) through human and rat skin in vitro. *Drug Chem*
462 *Toxicol*. 29:289-301; 2006

463 Schaefer-Korting, M.; Bock, U.; Diembeck, W.; Duesing, H.-J.; Gamer, A.; Haltner-
464 Ukomadu, E., et al. The use of reconstructed human epidermis for skin absorption testing:

465 results of the validation study. *Alternatives to laboratory animals* : ATLA. 36:161-187;
466 2008a

467 Schaefer-Korting, M.; Mahmoud, A.; Borgia, S.L.; Brueggener, B.; Kleuser, B.; Schreiber,
468 S., et al. Reconstructed epidermis and full-thickness skin for absorption testing: Influence
469 of the vehicles used on steroid permeation. *Alternatives to laboratory animals* : ATLA.
470 36:441-452; 2008b

471 Schafer-Korting, M.; Bock, U.; Gamer, A.; Haberland, A.; Haltner-Ukomadu, E.; Kaca, M.,
472 et al. Reconstructed human epidermis for skin absorption testing: results of the German
473 prevalidation study. *Alternatives to laboratory animals* : ATLA. 34:283-294; 2006

474 Stefaniak, A.B.; Harvey, C.J.; Wertz, P.W. Formulation and stability of a novel artificial
475 sebum under conditions of storage and use. *International journal of cosmetic science*.
476 32:347-355; 2010

477 UNEP. United Nations Environment Programme, Persistent Organic Pollutants Review
478 Committee (POPRC), Reports and Decisions.
479 [http://chmpopsint/TheConvention/POPsReviewCommittee/OverviewandMandate/tabid/28](http://chmpopsint/TheConvention/POPsReviewCommittee/OverviewandMandate/tabid/2806/Default.aspx)
480 [06/Default.aspx](http://chmpopsint/TheConvention/POPsReviewCommittee/OverviewandMandate/tabid/2806/Default.aspx); 2014

481 van der Veen, I.; de Boer, J. Phosphorus flame retardants: Properties, production,
482 environmental occurrence, toxicity and analysis. *Chemosphere*. 88:1119-1153; 2012

483 van Ravenzwaay, B.; Leibold, E. The significance of in vitro rat skin absorption studies to
484 human risk assessment. *Toxicol in Vitro*. 18:219-225; 2004

485 Watkins, D.J.; McClean, M.D.; Fraser, A.J.; Weinberg, J.; Stapleton, H.M.; Sjoedin, A., et al.
486 Exposure to PBDEs in the Office Environment: Evaluating the Relationships Between
487 Dust, Handwipes, and Serum. *Environ Health Persp*. 119:1247-1252; 2011

488 Wikoff, D.S.; Birnbaum, L. Human Health Effects of Brominated Flame Retardants. In:
489 Eljarrat EBD, ed. *Handb Environ Chem*; 2011

490 Zalko, D.; Jacques, C.; Duplan, H.; Bruel, S.; Perdu, E. Viable skin efficiently absorbs and
491 metabolizes bisphenol A. *Chemosphere*. 82:424-430; 2011

492

493 **Tables**

494 Table 1: Distribution of target BFRs (expressed as % of exposure dose) in different fractions
 495 of the *in vitro* diffusion system following 24 hour exposure to 500 ng/cm² of α -, β -, γ -
 496 HBCDs and TBBP-A in acetone.

	α -HBCD	β -HBCD	γ -HBCD	TBBP-A
EPISKIN™				
Receptor fluid (24h)	5.81 ± 1.04	3.86 ± 0.78	3.42 ± 0.94	6.29 ± 0.65
Receptor rinse	0.10 ± 0.02	0.07 ± 0.02	0.11 ± 0.02	0.41 ± 0.28
Directly absorbed fraction	5.90 ± 1.06	3.94 ± 0.82	3.46 ± 0.96	6.70 ± 0.92
Skin-Epidermis (Depot)	30.06 ± 2.42	27.18 ± 2.28	23.66 ± 3.16	24.18 ± 2.54
Skin wash (unabsorbed)	44.34 ± 4.04	51.47 ± 3.72	56.82 ± 4.58	53.53 ± 3.46
Donor rinse (unabsorbed)	5.13 ± 0.64	3.16 ± 0.82	2.38 ± 1.06	4.93 ± 2.08
Unabsorbed dose	49.47 ± 4.68	54.63 ± 4.54	59.20 ± 5.64	58.46 ± 5.54
Total Recovery	85.43 ± 8.16	85.75 ± 7.64	86.32 ± 9.76	89.34 ± 9.02
EpiDerm™				
Receptor fluid (24h)	6.35 ± 0.92	4.02 ± 1.04	3.74 ± 0.82	6.44 ± 0.59
Receptor rinse	0.11 ± 0.04	0.10 ± 0.08	0.09 ± 0.04	0.34 ± 0.16
Directly absorbed fraction	6.46 ± 0.94	4.13 ± 1.12	3.82 ± 0.86	6.78 ± 0.74
Skin-Epidermis (Depot)	28.19 ± 3.18	24.39 ± 2.22	21.02 ± 3.52	23.79 ± 2.42
Skin wash (unabsorbed)	45.73 ± 4.02	53.91 ± 3.44	58.84 ± 4.38	55.04 ± 4.29
Donor rinse (unabsorbed)	5.07 ± 0.62	2.39 ± 0.52	1.97 ± 0.74	4.11 ± 1.27
Unabsorbed dose	50.80 ± 4.64	56.30 ± 3.96	60.81 ± 5.12	59.15 ± 5.56
Total Recovery	85.45 ± 8.76	84.82 ± 7.30	85.65 ± 9.50	89.72 ± 8.72
Human <i>ex vivo</i> skin				
Receptor fluid (24h)	4.88 ± 1.44	3.21 ± 1.06	3.01 ± 1.02	5.37 ± 0.65
Receptor rinse	0.07 ± 0.02	0.11 ± 0.02	0.06 ± 0.02	0.21 ± 0.28
Directly absorbed fraction	4.95 ± 1.44	3.32 ± 1.06	3.07 ± 1.48	5.57 ± 0.92
Skin-Epidermis (Depot)	30.59 ± 2.28	27.82 ± 2.38	24.16 ± 2.24	24.71 ± 2.96
Skin wash (unabsorbed)	47.05 ± 4.44	51.19 ± 4.68	56.48 ± 3.28	56.53 ± 4.46
Donor rinse (unabsorbed)	5.23 ± 1.48	3.37 ± 1.02	2.07 ± 0.66	3.83 ± 2.08
Unabsorbed dose	52.28 ± 5.92	54.56 ± 5.70	58.55 ± 3.94	60.37 ± 6.54
Total Recovery	87.82 ± 7.84	85.70 ± 6.28	85.78 ± 7.38	85.65 ± 10.42

497

498

499

500

501


502 **Table 2:** Steady state flux, permeation coefficient and lag time values estimated for the target
 503 BFRs using different *in vitro* skin models.

	Flux (J_{ss}) (ng/cm².h)	Permeation coefficient (P_{app}) (cm/h)	Lag time (h)
EPISKIN™			
α-HBCD	1.25	2.50 x 10 ⁻⁰⁴	0.80
β-HBCD	0.84	1.69 x 10 ⁻⁰⁴	1.01
γ-HBCD	0.78	1.56 x 10 ⁻⁰⁴	1.21
TBBPA	1.47	2.93 x 10 ⁻⁰³	0.72
EpiDerm™			
α-HBCD	1.33	2.74 x 10 ⁻⁰⁴	0.77
β-HBCD	0.88	1.77 x 10 ⁻⁰⁴	0.97
γ-HBCD	0.85	1.72 x 10 ⁻⁰⁴	1.13
TBBPA	1.48	2.97 x 10 ⁻⁰³	0.60
Human <i>ex vivo</i> skin			
α-HBCD	1.08	2.16 x 10 ⁻⁰⁴	0.85
β-HBCD	0.74	1.47 x 10 ⁻⁰⁴	1.17
γ-HBCD	0.69	1.37 x 10 ⁻⁰⁴	1.26
TBBPA	1.29	2.58 x 10 ⁻⁰³	0.79

504
 505
 506
 507
 508
 509
 510
 511
 512
 513
 514


515 **Figures**

516 **Figure 1:** General outline of the experimental protocol applied for percutaneous permeation
517 experiments.



518
519
520
521
522
523
524
525
526

527 **Figure 2:** Cumulative dose absorbed into the receptor fluid following exposure of (a) human
528 *ex vivo* skin, (b) EPISKIN™ and (c) EpiDerm™ to 1000 ng/cm² of target BFRs over 24 h.




529

530

531

532 Figure 3: Cumulative permeation (ng/cm^2) into the receptor fluid following exposure of
533 EPISKINTM model to $500 \text{ ng}/\text{cm}^2$ of target BFRs in (A) acetone, (B) 30% acetone in water,
534 and (C) 20% Tween 80 in water for 24 h.



535

536

Supplementary Information

[Click here to download Supplementary Information: SI_Abdallah et al 2015_R1_NFC.docx](#)

